Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig and Bevacizumab in Recurrent Glioblastoma
NCT07297212Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in glioblastoma (GBM), sponsored by BioNTech SE. Started Jan 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07297212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297212.